Effect of Previous Anticoagulant Treatment on Risk of COVID-19

[1]  F. Gómez-Bertomeu,et al.  Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain , 2022, Medicina Clínica (English Edition).

[2]  K. Bhaskaran,et al.  Association between oral anticoagulants and COVID-19-related outcomes: a population-based cohort study , 2022, The British journal of general practice : the journal of the Royal College of General Practitioners.

[3]  K. Bhaskaran,et al.  Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study , 2021, Journal of Hematology & Oncology.

[4]  L. Lerman,et al.  Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19 , 2021, Mayo Clinic Proceedings.

[5]  M. Mckenney,et al.  Disparities in global COVID-19 vaccination rates & allocation of resources to countries in need , 2021, Annals of Medicine and Surgery.

[6]  H. Ohtsu,et al.  The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan , 2021, Journal of Infection and Chemotherapy.

[7]  S. Harrison,et al.  Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes , 2021, Thrombosis Research.

[8]  Tayfun Çalışkan,et al.  COVID-19 and thrombosis: Prophylaxis and management. , 2021, Tuberkuloz ve toraks.

[9]  Francisco Martín-Luján,et al.  “Susceptibilidad y riesgo de infección por SARS-COV-2 en adultos mayores de 50 años en el área de Tarragona” , 2021, Medicina Clínica.

[10]  M. Akbari,et al.  COVID‐19‐related coagulopathy: A review of pathophysiology and pharmaceutical management , 2021, Cell biology international.

[11]  P. McKeigue,et al.  Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study , 2021, BMC Medicine.

[12]  J. Alsac,et al.  Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID‐19: Insight From a French Multicenter Cohort Study , 2021, Journal of the American Heart Association.

[13]  B. Cheung,et al.  Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study , 2021, Pharmacological Research.

[14]  H. Thiele,et al.  Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany , 2021, Clinical Research in Cardiology.

[15]  E. Bernasconi,et al.  A data-driven approach to identify risk profiles and protective drugs in COVID-19 , 2020, Proceedings of the National Academy of Sciences.

[16]  J. Schmittdiel,et al.  Association of anticoagulation use with SARS-CoV2 detection☆ , 2020, Thrombosis Research.

[17]  J. Ludvigsson,et al.  Direct oral anticoagulant use and risk of severe COVID‐19 , 2020, Journal of internal medicine.

[18]  I. Casella.  Physiopathology of SARS-CoV-2-infection-associated thrombosis , 2020, Jornal vascular brasileiro.

[19]  J. Portillo Sánchez.  Prophylaxis of venous thromboembolism disease in patients with cancer. , 2020, Revista clinica espanola.

[20]  S. Ayis,et al.  The association between treatment with heparin and survival in patients with Covid-19 , 2020, Journal of Thrombosis and Thrombolysis.

[21]  L. Rodríguez-Mañas,et al.  Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.

[22]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[23]  K. Syrigos,et al.  Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action , 2020, British journal of haematology.

[24]  A. Figueiras,et al.  Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review , 2019, BMC Medical Research Methodology.

[25]  Neil Pearce,et al.  Analysis of matched case-control studies , 2016, British Medical Journal.

[26]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[27]  C. Huber,et al.  Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications , 2013, BMC Public Health.

[28]  W. Stroup.  Generalized Linear Mixed Models: Modern Concepts, Methods and Applications , 2012 .

[29]  Sherri Rose,et al.  The International Journal of Biostatistics Why Match ? Investigating Matched Case-Control Study Designs with Causal Effect Estimation , 2011 .

[30]  Simon French,et al.  Encyclopedia of quantitative risk analysis and assessment , 2008 .

[31]  Robin J. Prescott,et al.  Applied Mixed Models in Medicine: Brown/Applied Mixed Models in Medicine, 2nd Edition , 2006 .

[32]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[33]  M. de la Figuera,et al.  [Differences in the management of patients with atrial fibrillation according to whether primary care or the specialist initiates treatment with direct oral anticoagulants. The SILVER-AP and BRONCE-AP studies]. , 2017, Semergen.

[34]  A. Hoes.  Case-control studies. , 1995, The Netherlands journal of medicine.